SI-BONE, Inc. (NASDAQ:SIBN) Receives $23.00 Consensus Target Price from Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) have earned an average rating of "Buy" from the six research firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $23.00.

Several equities research analysts recently issued reports on SIBN shares. Needham & Company LLC reissued a "buy" rating and issued a $19.00 price objective on shares of SI-BONE in a research note on Monday, January 13th. Truist Financial increased their price target on shares of SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th.

Insider Activity

In related news, CFO Anshul Maheshwari sold 2,439 shares of the company's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the sale, the chief financial officer now directly owns 194,623 shares in the company, valued at approximately $2,467,819.64. This represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Anthony J. Recupero sold 3,937 shares of the firm's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.60, for a total value of $49,606.20. Following the transaction, the insider now owns 228,554 shares in the company, valued at approximately $2,879,780.40. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,344 shares of company stock worth $357,292 in the last three months. 3.90% of the stock is owned by insiders.

Institutional Investors Weigh In On SI-BONE

A number of large investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company grew its position in shares of SI-BONE by 7.5% in the second quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company's stock valued at $205,000 after purchasing an additional 1,105 shares during the last quarter. FMR LLC grew its holdings in SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company's stock valued at $33,000 after buying an additional 1,198 shares during the last quarter. Rhumbline Advisers increased its position in SI-BONE by 3.0% in the 4th quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock worth $808,000 after buying an additional 1,683 shares during the period. Franklin Resources Inc. increased its position in SI-BONE by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock worth $265,000 after buying an additional 1,745 shares during the period. Finally, Mainstream Capital Management LLC acquired a new position in shares of SI-BONE during the fourth quarter worth approximately $53,000. Institutional investors own 98.11% of the company's stock.

SI-BONE Trading Down 1.2 %

NASDAQ:SIBN traded down $0.20 during trading hours on Thursday, hitting $17.08. 198,330 shares of the stock traded hands, compared to its average volume of 312,104. The firm has a 50 day moving average price of $14.95 and a 200 day moving average price of $14.53. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE has a fifty-two week low of $11.70 and a fifty-two week high of $21.64.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.